Welcome to our dedicated page for Invivyd SEC filings (Ticker: IVVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Invivyd, Inc. filings document material events, governance matters, capital actions, and financial-result disclosures for a Nasdaq-listed biopharmaceutical company developing monoclonal antibodies for serious viral infectious diseases. Recent Form 8-K reports furnish operating results, preliminary product revenue information for PEMGARDA, corporate presentations, and program updates involving COVID-19, RSV, and measles antibody candidates.
The filing record also includes a definitive proxy statement covering annual-meeting matters such as director elections and auditor ratification, as well as an 8-K describing a completed underwritten public offering of common stock and pre-funded warrants. These disclosures describe the company’s common stock, financing activity, board governance, research and development priorities, and commercial preparedness around its antibody portfolio.
RA Capital Management and affiliated filers amended their Schedule 13G to report beneficial ownership tied to pre-funded warrants for Invivyd, Inc. The amendment states the Fund holds Pre-Funded Warrants exercisable for 21,342,442 shares of Common Stock and reports 7.0% of the class as of March 31, 2026.
The percentage is calculated using 282,803,863 shares outstanding as of March 20, 2026 plus the 21,342,442 shares issuable upon exercise of the Pre-Funded Warrants. The filing discloses that voting and dispositive power over the Fund's holdings has been delegated to RA Capital and contains standard disclaimers of beneficial ownership by the advisers and principals.
Invivyd, Inc. reporting persons Point72 Asset Management, Point72 Capital Advisors, Inc. and Steven A. Cohen filed an Amendment No. 3 to a Schedule 13G/A stating shared beneficial ownership of 43,931 shares of common stock. The ownership figure is reported as of the close of business on March 31, 2026.
The cover-page rows show shared voting power and shared dispositive power of 43,931 for each reporting person. The amendment lists the reporting persons' principal business address and is signed by an authorized person on May 15, 2026.
Invivyd, Inc. reported higher product revenue but significantly larger losses for the quarter ended March 31, 2026. Revenue rose to $13.7 million from $11.3 million, driven by sales of its COVID-19 antibody PEMGARDA. Operating costs climbed sharply, with research and development at $30.7 million and selling, general and administrative at $25.1 million, leading to a net loss of $41.4 million, up from $16.3 million a year earlier.
Cash and cash equivalents fell to $184.2 million from $226.7 million at year-end, with operating cash outflows of $41.7 million in the quarter and an accumulated deficit of $995.9 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond one year without additional financing. Invivyd continues advancing its pipeline, including Phase 3 trials for COVID-19 antibody VYD2311 and preclinical RSV and measles programs, while also maintaining access to an undrawn senior loan facility and an at-the-market equity program.
Invivyd, Inc. reported first quarter 2026 results showing growing product sales alongside higher spending as it advances its COVID-19 antibody pipeline. Net product revenue reached $13.7 million, up from $11.3 million a year earlier, driven by continued uptake of PEMGARDA for immunocompromised patients.
Total operating costs and expenses rose to $56.9 million, largely from research and development and commercial build-out, leading to a net loss of $41.4 million compared with a $16.3 million loss in the prior-year quarter. Cash and cash equivalents were $184.2 million as of March 31, 2026, supplemented by additional ATM proceeds in April.
The company highlighted rapid enrollment in its DECLARATION Phase 3 pivotal study of VYD2311, plans for the LIBERTY safety and combination trial with an mRNA COVID vaccine, and a pediatric program design agreed with the FDA. Invivyd is also advancing earlier-stage antibodies targeting measles (VMS063) and RSV (VBY329) while expanding commercial infrastructure for a potential VYD2311 launch.
Invivyd, Inc. provides detailed updates on its COVID-19 antibody program and unveils a new measles antibody candidate. The pivotal Phase 3 DECLARATION study of VYD2311 for pre-exposure COVID-19 prophylaxis has been upsized by about 500 participants beyond an initial 1,818, after a pre-specified, conservative, blinded sample size re-estimation showed enough events to support high-end efficacy targets. Top-line data are now expected in the third quarter of 2026, with a pediatric VYD2311 study in children 0–11 years, called DRUMMER, planned only if DECLARATION is successful. Invivyd also introduces VMS063, a highly potent, half-life-extended measles monoclonal antibody targeting the conserved Fusion protein, showing picogram- to low-nanogram-per-milliliter neutralization in vitro across key measles lineages. VMS063 has entered IND-enabling work for near-term clinical development, aimed at treatment and prophylaxis in high-risk groups amid rising U.S. measles cases and waning herd immunity.
Invivyd, Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on May 19, 2026 at 8:30 a.m. Eastern Time. Stockholders will elect six directors for one-year terms expiring at the 2027 meeting and ratify PricewaterhouseCoopers LLP as auditor for 2026.
The Board unanimously recommends voting “FOR ALL” director nominees and “FOR” auditor ratification. The meeting is fully virtual at www.virtualshareholdermeeting.com/IVVD2026, with a record date of March 20, 2026, when 282,803,863 common shares were outstanding and entitled to one vote each.
Invivyd, Inc. (IVVD) is a clinical‑stage biopharmaceutical company focused on monoclonal antibodies for serious viral infections, led by COVID‑19. Its only authorized product is PEMGARDA, an EUA‑cleared antibody for pre‑exposure COVID‑19 prophylaxis in certain moderately to severely immunocompromised patients in the U.S.
The company’s future depends heavily on PEMGARDA’s commercial uptake and continued emergency authorization, and on advancing VYD2311, a next‑generation COVID‑19 antibody now in Phase 3 prevention trials under FDA Fast Track. Invivyd is also developing VBY329 for RSV in infants and an early measles antibody program.
The filing highlights substantial doubt about the company’s ability to continue as a going concern, ongoing losses, and the need for additional funding. Invivyd relies on key partners, including WuXi Biologics for manufacturing and Adimab for antibody discovery and platform technology, and operates in a competitive landscape with vaccines, antivirals, and other antibody developers.
Invivyd, Inc. reported strong 2025 growth as net product revenue rose to $53.4M from $25.4M, driven by PEMGARDA sales, while operating expenses fell sharply. The company’s net loss narrowed to $52.5M from $169.9M, and year-end cash and equivalents increased to $226.7M, supported by over $200M raised in the second half of 2025.
PEMGARDA quarterly net product revenue reached $17.2M in Q4 2025, up 25% year over year and 31% sequentially, helping build a commercial foundation. Invivyd advanced its pipeline, fully enrolling the Phase 3 DECLARATION trial of COVID-19 antibody VYD2311, gaining Fast Track designation and targeting top-line data mid-year, while nominating RSV candidate VBY329 and planning a SPEAR Long COVID study.
Invivyd, Inc. Chief Scientific Officer Robert D. Allen III reported RSU vesting and related stock sales. He acquired 99,000 shares of common stock at $0.0000 per share through the exercise/conversion of restricted stock units and then sold 37,581 shares in open-market transactions.
The sales, at weighted average prices of $1.5396 and $1.5778 per share, were made under a non-discretionary sell-to-cover arrangement to satisfy tax withholding obligations pursuant to a Rule 10b5-1 plan. After these transactions, he directly held 114,487 shares of Invivyd common stock.